• Resize Text
    • Small Text
    • Medium Text
    • Large Text
    • Connect

Rosemont Pharmaceuticals to acquire Aytu BioPharma to accelerate US expansion

Rosemont Pharmaceuticals Holdings, Inc. (“Rosemont”), a global specialty pharmaceutical company focused on designing and delivering medicines around patients’ needs, today announced that it has entered into a definitive merger agreement to acquire Aytu BioPharma, Inc. (“Aytu”) (Nasdaq: AYTU), a US specialty pharmaceutical company focused on advancing innovative medicines for complex central nervous system (CNS) diseases.

The proposed acquisition represents a significant step in Rosemont’s global growth strategy, building on its established US presence and strengthening its position in the specialty pharmaceutical market. By bringing together complementary portfolios, expertise and commercial capabilities including omnichannel and digital marketing expertise, Rosemont aims to accelerate growth, expand its reach and create new opportunities across international markets.

Rosemont Pharmaceuticals is backed by Inflexion, a leading European-headquartered mid-market private equity firm with investing offices in London, New York, Amsterdam, Frankfurt and Stockholm. Inflexion has $21bn of assets under management and a dedicated on-the-ground team in New York City which was established in 2025.

Alok Sonig, Chief Executive Officer of Rosemont Pharmaceuticals, said: “The proposed acquisition of Aytu marks an important step in Rosemont’s US growth strategy. Aytu has built an established CNS adult and paediatric-focused specialty pharmaceutical business with talented people, a differentiated portfolio and proven commercial capabilities. Together with Rosemont’s product development, regulatory, manufacturing and commercial expertise, we believe we can build a strong platform for future growth. We look forward to welcoming the Aytu team once the transaction is complete.”

Josh Disbrow, Chief Executive Officer of Aytu BioPharma, said: “This agreement with Rosemont reflects the work our team has done to build our CNS and pediatric portfolio and earn the trust of the patients and healthcare providers we serve. We see a strong strategic fit between our portfolio and Rosemont’s experience developing and commercializing specialty medicines. Importantly, we believe the transaction delivers compelling value to our shareholders and that, together, we can help more patients get the treatment they need.”

Under the terms of the merger agreement, a wholly owned subsidiary of Rosemont will commence a tender offer to acquire all outstanding shares of Aytu common stock at $2.70 per share in cash. The price represents a 41.1% premium to Aytu’s 30-day volume-weighted average share price. The transaction is structured as a tender offer to be followed by a merger, subject to customary conditions to the tender offer and merger, including the tender of shares representing at least a majority of the total number of outstanding shares of Aytu common stock and the exercise or termination of certain of Aytu’s outstanding warrants.

Following the successful completion of the tender offer, Rosemont will acquire all remaining shares not tendered in the tender offer (other than shares for which appraisal rights are properly exercised) through a second-step merger at the same price paid in the tender offer.

Rosemont intends to commence the tender offer and file a Schedule TO within 10 business days, and Aytu will file a Schedule 14D-9 with respect to the tender offer substantially concurrently with the commencement of the tender offer, each of which will include additional details on the transaction and process undertaken by the Company.

The transaction was unanimously approved by the Aytu board of directors and closing is anticipated to occur in late December 2026, subject to the satisfaction or waiver of the conditions to the tender offer. Aytu’s executive officers, directors and certain stockholders affiliated with Nantahala Capital Management and Stonepine Capital Management have signed tender and support agreements under which such stockholders agreed, among other things, to tender their shares in the tender offer and to the termination or exercise of any warrants held by them prior to the Effective Time, in exchange for the consideration payable in connection with the transaction in accordance with the terms of such warrants.

Until the proposed acquisition completes, Rosemont and Aytu will remain separate companies and continue to operate independently. Following completion, a key priority will be ensuring a smooth transition, maintaining continuity of supply and service for customers and partners, and keeping the needs of patients and healthcare professionals at the heart of everything we do.

Bourne Partners is acting as financial adviser to Rosemont, and Ropes & Gray LLP is serving as Rosemont’s legal counsel. Canaccord Genuity is acting as financial adviser to Aytu BioPharma and Dorsey & Whitney LLP is serving as its legal counsel.